Background: A Norwegian community study was conducted as an add-on to a large general health survey in Trondlag County, Norway, to characterize the cross-sectional relationship of patient perceptions with the degree of hair loss. Methods: All members of the community were invited to participate in the general health survey and male participants, aged 20–50 years (n = 7,250), regardless of their degree of hair loss, were asked to complete a mail-based questionnaire. The questionnaire measured satisfaction with hair appearance, self-reported degree of hair loss, self-assessment of Norwood/Hamilton hair pattern, bother due to hair loss as well as concern about getting older due to hair loss, and included the SF-12 general health status questionnaire. Results: Respondents (n = 4,101) rated their hair loss on a 7-point, textual scale that ranged from ‘a full head of hair’ to ‘I am bald’. The majority (63%) of participants reported at least a little hair loss and 27% reported moderate to severe loss. Using the Norwood/Hamilton hair patterns, participants rated themselves as class II (25.5%), III (8.6%), IV (8.8%) or V or worse (19.5%). Relative to men without hair loss, a greater proportion of men with hair loss reported being bothered (20.5 vs. 2.3%), concerned about growing older (43.4 vs. 10.6%) and dissatisfied with overall hair appearance (22.6 vs. 94%, all p ≤ 0.001). Men with hair loss also reported greater levels of perceived noticeability of hair thinning to others. Conclusions: A high proportion of Norwegian men aged 26–50 years self-reported having at least some hair loss. Results suggest that men who perceive themselves as having greater hair loss are more bothered by their hair loss, more dissatisfied with the appearance of their hair and have greater concern about getting older and losing more hair.

Keywords:
Androgenetic alopecia, Community-based survey, Norway
1.
Hamilton JB: Patterned loss of hair in man: Types and incidence. Ann NY Acad Sci 1951;53:708–728.
2.
Norwood O: Male pattern baldness: Classification and incidence. South Med J 1975;68:1359–1365.
3.
Ware JE, Kosinski M, Keller SD: SF-12: How to score the SF-12 Physical and Mental Health Summary Scales, ed 1. Boston, Health Institute, New England Medical Center, 1995.
4.
Berwick DM, Murphy JM, Goldman PA, Ware JE, Barsky AJ, Weinstein MC: Performance of a five-item mental health screening test. Med Care 1991;29:169–176.
5.
Barber BL, Kaufman KD, Kozloff RC, Girman CJ, Guess HA: A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatol Treat 1998;9:181–186.
6.
Girman CJ, Rhodes T, Lilly FR, Guo SS, Siervogel RM, Patrick DL, Chumlea WC: Effects of self-perceived hair loss in a community sample of men. Dermatology 1998;197:223–229.
7.
Gagnon D, McNulty P, Buesching DP, Patrick DL: Change in quality of life in a study of male minoxidil users. Drug Information J 1993;27:871.
8.
Rhodes T, Girman CJ, Savin RC, Kaufman KD, Guo S, Lilly FR, Siervogel RM, Chumlea WC: How common is male pattern hair loss in the community? Dermatol Surg 1998;24:1330–1332.
9.
Budd D, Himmelberger D, Rhodes T: A survey on the effects of hair loss in European men in four countries. Br J Dermatol, in press.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.